Assessment of the Safety and Effectiveness of Stem Cell Treatments for Dry Eye Syndrome Associated with Sjögren’s Syndrome: A Systematic Review and Meta-Analysis - Report - MDSpire
Advertisement
Assessment of the Safety and Effectiveness of Stem Cell Treatments for Dry Eye Syndrome Associated with Sjögren’s Syndrome: A Systematic Review and Meta-Analysis
Safety and Effectiveness of Stem Cell Therapy for Sjögren’s Dry Eye Syndrome
Overview
This systematic review and meta-analysis of five studies involving 114 patients demonstrates that stem cell therapy significantly improves key clinical measures of dry eye syndrome associated with Sjögren’s syndrome, including OSDI and Schirmer test scores. While treatment shows promise in enhancing tear film stability, a notable incidence of short-term adverse events necessitates careful risk-benefit assessment.
Background
Sjögren’s syndrome is a chronic autoimmune disorder characterized by severe dry eye disease (DED), primarily due to aqueous deficiency. Current treatments, including artificial tears and immunosuppressants, often provide limited relief and carry risks of long-term side effects. Stem cells, particularly mesenchymal stem cells, offer immunomodulatory and anti-inflammatory effects, making them a promising therapeutic option for SS-associated DED. This review systematically evaluates the efficacy and safety of stem cell therapies in this patient population.
Data Highlights
Outcome
Mean Difference (MD)
95% CI
P-value
OSDI Score
-15.10
-18.65 to -11.56
<0.00001
NIKBUT First
3.26
2.17 to 4.34
<0.0001
Oxford Score
-0.20
-0.85 to 0.45
0.55
Schirmer Test Overall
3.87
1.93 to 5.81
<0.0001
Schirmer Test at 2 weeks
8.76
0.58 to 16.94
0.04
Schirmer Test at 4 months
3.52
1.66 to 5.38
0.002
Schirmer Test at 12 months
5.10
0.24 to 9.96
0.04
Key Findings
Stem cell therapy significantly reduced Ocular Surface Disease Index (OSDI) scores by a mean of 15.10 points, indicating symptom improvement.
Non-invasive Keratograph Break-Up Time (NIKBUT) first scores increased by 3.26 points, reflecting enhanced tear film stability.
Schirmer test scores, measuring tear production, improved significantly overall and at multiple time points up to 12 months post-treatment.
The Oxford score, assessing ocular surface damage, did not show a statistically significant change post-treatment.
Adverse events such as injection pain (14%), ocular discomfort (16%), periorbital oedema (14%), blurred vision (21%), and periorbital paresthesia (15%) were reported within 4 weeks, though not statistically significant.
Clinical Implications
Stem cell therapy offers a promising treatment avenue for patients with Sjögren’s syndrome-associated dry eye by improving symptoms and tear production. However, clinicians should carefully weigh the benefits against the risk of short-term adverse events and ensure rigorous patient monitoring and follow-up during treatment. Further large-scale studies are warranted to confirm long-term safety and efficacy.
Conclusion
Stem cell therapy effectively improves clinical signs and symptoms of dry eye syndrome in Sjögren’s syndrome patients, but the potential for adverse events requires cautious clinical application with close monitoring.
Dr. Theriot discusses the differences between natural tear film and artificial tears—and why the change in moniker to "lubricating drops" is appropriate.
